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Summary. Inflammatory Bowel Disease (IBD), which includes both Crohn’s Disease (CD) and Ulcerative Co-
litis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Diet, as a source of 
luminal antigens, is thought to be an important factor in the pathogenesis of IBD. Often the nutritional status of 
patients is significantly compromised, particularly in CD. Several factors, including drug-nutrient interactions, 
disease location, symptoms, and dietary restrictions can lead to protein energy malnutrition and specific nutri-
tional deficiencies. Solid evidence regarding the accountability of certain dietary components in the etiology of 
IBD are lacking. With regard to malnutrition, its consequence are growth failure, weight loss, bone disease, and/
or micronutrient deficiencies, although micronutrient deficiency in IBD in most cases does not tend to have any 
evident clinical manifestation, except with regard to iron, folic acid, and vitamin B. Nutritional supplementation 
is essential for patients with evidence of malnutrition to increase calorie and protein intake. Nutritional supple-
mentation can also have efficacy in the induction and maintenance of remission in adults with CD, however it 
does not replace other treatments. Aim of this review is to discuss the role of nutrition and nutrients’ deficiencies 
in the clinical setting of IBD, and to analyze efficacy and safety of the dietary interventions in patients with IBD.
Key words: Nutrition, malnutrition, diet, inflammatory bowel disease, IBD, crohn’s disease, ulcerative colitis
«Nutrizione, malnutrizione e regime dietetico nelle malattie infiammatorie intestinali»
Riassunto. Le Malattie infiammatorie intestinali (IBD), che comprendono sia la malattia di Crohn (CD) sia la 
Colite ulcerosa (UC), sono delle malattie infiammatorie croniche idiopatiche che colpiscono il tratto gastroin-
testinale. Si pensa che la dieta, in quanto fonte di antigeni luminali, sia un fattore importante nella patogenesi 
delle IBD. Lo stato nutrizionale di pazienti spesso risulta essere significativamente compromesso, specie nella 
CD. Diversi fattori, tra cui le interazioni tra farmaci e nutrienti, la localizzazione della malattia, i sintomi e le 
restrizioni dietetiche, possono portare a malnutrizione sia proteica che energetica e a specifiche carenze nutri-
zionali. Solide evidenze sussistono per quanto riguarda la responsabilità della carenza di alcuni componenti della 
dieta nell’eziologia delle IBD. Le conseguenze della malnutrizione sono la mancata crescita, la perdita di peso, 
alterazioni a livello osseo, e le carenze di micronutrienti; anche se la carenza di micronutrienti nelle IBD non 
Progress in Nutrition 2014; 16; 2: 79-89                      © Mattioli 1885
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Introduction
Inflammatory Bowel Disease (IBD), which in-
cludes both Crohn’s Disease (CD) and Ulcerative Co-
litis (UC), is a chronic idiopathic inflammatory disor-
der affecting the gastrointestinal tract. (1). CD and UC 
affect more than 1 million people in the United States, 
with thousands of new diagnoses annually (2,3).  The 
natural history of CD and UC is characterized by re-
peated episodes of inflammation and ulceration of the 
bowel. This results in complications implying a worse 
quality of life and significant healthcare costs, due to 
hospitalization, surgery and an escalation of therapy 
(4-6).
IBD lead to to symptoms of pain, nausea, fever, 
and diarrhoea (7). These symptoms can result in loss of 
appetite, reduced nutrient intake, altered nutrient me-
tabolism, and ultimately impaired nutritional status, as 
a result of the release of cytokines such as IL-1, IL-6, 
and tumor necrosis factor.
Diet, as a source of luminal antigens, is thought 
to be an important factor in the pathogenesis of IBD, 
but whether antibodies against dietary antigens play 
a primary role in IBD aetiology or are secondary to 
intestinal inflammation is yet to be established. In such 
endeavour, epidemiologic observations may become 
valuable for identifying dietary factors, which are in-
volved in the aggravation or otherwise promote disease 
remission. 
In IBD, nutritional status of patients is signifi-
cantly compromised, particularly in CD. Several factors, 
including drug-nutrient interactions, disease location, 
symptoms, and dietary restrictions can lead to protein 
energy malnutrition and specific nutritional deficiencies. 
It is estimated that up to 85% of hospitalized IBD pa-
tients have protein energy malnutrition, based on abnor-
mal anthropometric and biochemical parameters (8,9).
As Crohn’s disease can occur anywhere in gastro-
intestinal tract, from mouth to anus (80% of cases in 
the terminal ileum), it is associated with greater nutri-
tional insult than UC, which involves only the colon 
and rectum.
Currently various dietary interventions or supple-
ments are available for such patients (10,11).
Aim of this review is to discuss the role of nutri-
tion and nutrients’ deficiencies in the clinical setting of 
IBD, and to analyze efficacy and safety of the dietary 
interventions in patients with IBD.
Nutrition and pathogenesis of inflammatory bowel 
disease
IBD results from the interaction of three essential 
cofactors: genetic susceptibility, environment and the 
immune response of the individual (12).
The ultimate causes of IBD have not yet been 
identified, but epidemiological studies show differ-
ences in the rate of IBD in terms of age and onset, 
race and geographical areas (13,14). The existence of 
environmental factors is therefore suggested, which are 
capable of substantially altering the appearance of CD 
and UC (15).
Various dietary and nutritional factors have been 
suggested as being significant etiological factors both 
for CD and UC.
Several authors have reported that fats (16,17) as 
well as refined sugar (16,18-23) increased the risk of 
tendono ad avere, nella maggior parte dei casi, alcuna manifestazione clinica evidente, tranne che per quanto 
riguarda il ferro, l’acido folico e la vitamina B. Una supplementazione nutrizionale è fondamentale per i pazienti 
con evidenza di malnutrizione per aumentare l’apporto di calorie e proteine. Una supplementazione nutrizionale 
può anche avere efficacia nella induzione e nel mantenimento della remissione in pazienti adulti affetti da CD, 
tuttavia tale supplementazione non è capace di sostituirsi ad altri trattamenti. Scopo di questa review è quello di 
discutere il ruolo della nutrizione e delle sue carenze nell’ambito clinico delle IBD, e di analizzare l’efficacia e la 
sicurezza degli interventi dietetici nei pazienti con IBD.
Parole chiave:  Nutrizione, malnutrizione, dieta, malattie infiammatorie croniche dell’intestino, MICI, ma-
lattia di Crohn, colite ulcerosa
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developing IBD, while fruits (19,24,25) and vegetables 
(16,19,24,25) decreased this risk.
With regard to CD, in a case–control study, per-
formed by Sakamoto and coworkers, CD patients and 
normal individuals were given a semiquantitative food 
frequency questionnaire to estimate the pre-illness in-
take of food groups and nutrients (17). The investiga-
tors found that intakes of total fat, monounsaturated 
fatty acids, and PUFAs (both n-3 and n-6) were posi-
tively associated with IBD risk. Perhaps the relation-
ship between a high fat diet and IBD was thought to 
be related to the digestive process associated with these 
diets. Furthermore, various studies have shown that 
new consumption patterns, such as fast food, could be 
linked to an increased risk in the development of CD 
and UC (26,27). In addition, the consumption of large 
amounts of monounsaturated and polyunsaturated fats 
are both associated with a higher risk of UC (28,29).
The further observation that the Eskimos in 
Greenland, consumers of large quantities of n-3 poly-
unsaturated fatty acids (PUFAs) deriving from fish 
oils, had a low prevalence of IBD (30,31) led to the 
study of the anti-inflammatory properties of n-3 PU-
FAs (32), in comparison with pro-inflammatory n-6 
PUFAs. The latter have been clearly implicated in the 
origin of IBD, given that they affect the arachidonic 
acid metabolism by increasing the production of leu-
kotriene B4, with pro-inflammatory action. These 
discoveries have opened up new windows of action 
regarding the ability of lipids in the diet to regulate 
inflammatory processes in different diseases, as they 
are the fundamental component of cell membranes, 
including those of lymphocytes, which orchestrate im-
mune system responses (33).
With regard to sugars, previous studies have indi-
cated the high consumption levels of sugar and refined 
carbohydrates in patients with IBD (34,35) to the extent 
that they are now considered a risk factor for CD (36-38) 
and UC (39-41). Conversely, the consumption of citrous 
fruit, fruit juices and vegetables could lower the risk (42) 
of the development of both diseases (43-45), and a study 
has also showed an inverse relationship between the con-
sumption of bran and the onset of CD (46). 
Up to now, it has been impossible to determine 
whether the potentially protective effect is due to the 
action of the fiber or to other micronutrients contained 
in fruit and vegetables. The utility of low refined carbo-
hydrate diets in the treatment of CD has been suggest-
ed by several authors, although extensive clinical trials 
have not confirmed the benefits of this measure (47).
Scanty data are available about the role of proteins 
and calories in diet in the pathogenesis of IBD, even if 
some studies have suggested that the intake of proteins 
(29, 48) and calories (29) might be higher in patients 
with IBD compared to controls.
To date, solid evidence regarding the account-
ability of certain dietary components in the etiology of 
IBD are lacking, although the data discussed above al-
low to us to consider that the changes in the composi-
tion and characteristics of the diet which typifies mod-
ern life have been accompanied by substantial changes 
in the epidemiology of IBD in developed counties. 
Malnutrition in inflammatory bowel disease
In both Crohn’s disease and ulcerative colitis, 
malnutrition is the result of numerous pathogenic fac-
tors including anorexia, malabsorption, altered me-
tabolism, and fluid and electrolyte loss, as well as side 
effects of medications (49).
Nutritional deficiencies occur very early in the 
disease process and are often clinically apparent at the 
time of diagnosis. The pattern and severity of malnu-
trition in IBD depends on the duration, activity and 
extent of the disease, with significant differences hav-
ing been described between CD and UC, given that 
the involvement of the small intestine is accompanied 
by a higher incidence of protein-calorie malnutrition 
and deficiencies in specific nutrients (50).
Jahnsen, and coworkers, emphasizes differences 
in nutritional status between ulcerative colitis and 
Crohn’s disease, and the need to evaluate these patients 
separately (51).
Furthermore, CD presents considerable chronic 
deficiencies, whereas in UC, the nutritional status 
tends to be more preserved, although during the flares 
of activity of the disease and in cases of hospitalization, 
the deficiencies tend to be significant (52).
Consequences of malnutrition are growth failure, 
weight loss, bone disease, and/or micronutrient defi-
ciencies; the latter will be reviewed here, considering 
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however that although micronutrient deficiency in 
IBD is common, in most cases it does not tend to have 
any evident clinical manifestation, except with regard 
to iron, folic acid, and vitamin B12 (15).
Vitamins deficiency
Folate deficiency, which may lead to the develop-
ment of anemia in patients with IBD, was frequently 
observed in adults with IBD (20-60%, according to 
previous series), and but it appear less frequent in stud-
ies from the last decade (53,54). This historical differ-
ence could reflect changes in medical therapy (eg, less 
use of sulfasalazine) and/or higher levels of folate intake 
through supplements or foods. In fact treatment with 
sulfasalazine may exacerbate folate deficiency, since the 
drug’s sulfa moiety can bind folate in the gut lumen, 
leaving it unavailable for absorption. This is not true for 
other aminosalicylates, such as mesalamine. Treatment 
with methotrexate (a folic acid antagonist) can also con-
tribute to folate deficiency. In modern series of children 
with newly diagnosed IBD, folate concentrations were 
normal or higher than those of controls (55,56). 
Interestingly, the absence of folic acid has been re-
lated to the increased risk of colitis-associated carcino-
genesis, as well as it is also linked to the increased in-
cidence of arterial and venous thromboembolic events 
observed in CD and UC (15).
Vitamin B12 deficiency, which also can contrib-
ute to the increased incidence of anemia seen in pa-
tients with IBD, has been reported in about 20 per-
cent of adult and pediatric patients with CD (57,58) 
although it appears to be rare in children with newly 
diagnosed IBD (56). Factors leading to vitamin B12 
deficiency include disease or resection of the terminal 
ileum, gastritis, and bacterial overgrowth. With regard 
to niacin, Low plasma concentrations of this vitamin 
are common among patients with CD, but clinically 
apparent disease is rare.
Fat-soluble vitamin deficiency (vitamins A, D, E, 
and K) may occur in patients with CD when compli-
cated by fat malabsorption, which can be caused by 
bile acid deficiency due to terminal ileal disease or re-
section (because bile acids undergo active resorption 
in the terminal ileum), or by the use of drugs, such as 
cholestyramine, that bind bile acids.
Vitamin A (retinol) deficiency has been reported 
in IBD in about 5 percent of patients, which may de-
velop impaired dark adaptation. However, low serum 
levels of vitamin A do not always indicate clinical defi-
ciency because this finding can be caused by hypopro-
teinemia (59).
Vitamin D deficiency (<10 ng/mL ) is common in 
IBD patients, with an incidence reported to be up to 
25% in adults, and up to 36% in children. (60-63). En-
vironmental factors, such as diet and sun exposure, as 
well as factors related to the IBD itself (malabsorption 
and anorexia) may lead to deficiency of this vitamin. 
Individuals with malabsorption or established vi-
tamin D deficiency may require higher doses of vita-
min D to reach target levels of serum 25-hydroxyvita-
min D. In such patients, the adequacy of the calcium 
and vitamin D supplementation should be confirmed 
by measurements of serum 25-hydroxyvitamin D and, 
according some authors, of PTH. As for vitamin D, 
Vitamin K deficiency may be a contributor to bone 
disease in individuals with IBD because this vitamin is 
a cofactor in the carboxylation of osteocalcin, a protein 
essential for calcium binding to bone (64,65) even if 
this association is based on indirect evidence.
Vitamin E were proved to be lower in adult pa-
tients with IBD as compared with healthy controls 
but this was not the case in a series in children while 
deficient serum vitamin E levels (eg, <0.5 mg/dL) are 
unusual (66,67). It has been suggested that depletion 
of vitamin E and other antioxidant vitamins (such as 
retinol) may contribute to the pathogenesis of IBD, 
but such pathways have not been yet established.
Minerals deficiency
Iron deficiency, affecting up to 90% of IBD adult 
patients, is probably the primary cause of the anemia 
that affects 16 percent of outpatients and up to 70 
percent of inpatients (53,68). Iron deficiency in IBD 
is usually caused by chronic blood loss. The resulting 
anemia is compounded by suppression of erythro-
poietin production and alteration of iron metabolism 
caused by proinflammatory cytokines, reactive oxygen 
metabolites, and nitric oxide, a condition called the 
anemia of chronic inflammation (anemia of chronic 
disease).
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Patients with IBD should be screened for iron de-
ficiency periodically by measuring hemoglobin, ferri-
tin, and C-reactive protein (CRP). However, as serum 
ferritin levels increase in the setting of inflammation, 
patients with active IBD or acute infection may have 
a “falsely” normal ferritin concentration. In patients 
without biochemical or clinical evidence of inflam-
mation, iron deficiency is indicated by a serum ferri-
tin <30 mcg/L. In the presence of inflammation (eg, 
with an elevated CRP), serum ferritin levels below 100 
mcg/L should be considered abnormal.
In patients with mild to moderate IBD disease 
activity who have no known sensitivity to oral iron, 
we suggest supplementation with oral iron. In patients 
with severe IBD disease activity, we suggest parenteral 
iron supplementation to avoid worsening gastrointes-
tinal symptoms, since these patients are already partic-
ularly fragile. In adults, other indications for parenteral 
iron supplementation include hemoglobin less than 10 
grams per dL, intolerance, or inadequate response to 
oral iron, concomitant therapy with an erythropoietic 
agent, or patient preference (69).
Up to 65 percent of patients with CD have zinc 
deficiency (56,70,71). However, serum zinc levels vary 
with albumin and correlate poorly with total body zinc 
stores; clinically significant zinc deficiency is probably 
much less common. 
Excessive losses of zinc may be observed in pa-
tients with ostomies, fistulas, and profuse diarrhea, 
or in those with prolonged parenteral nutrition un-
less trace minerals are included. The skin changes are 
the most distinctive manifestations of zinc deficiency, 
which consist of dry scaly eczematous plaques, often 
on the face and anogenital area, often resembling pso-
riasis. 
Zinc is a vital component for the healing of 
wounds and its deficiency should be considered in the 
case of recurrent fistulous disease (72,73).
In addition, zinc is a co-factor of superoxide dis-
mutase, which protects against cell damage caused by 
free radicals. Symptomatic zinc deficiency in patients 
with IBD is treated with oral or parenteral zinc at re-
placement doses.
Approximately 13 percent of adults with CD ma-
labsorbs calcium (74), as a result of the binding of cal-
cium to undigested fats in the intestinal lumen, of loss 
of the ileum leading to vitamin D deficiency, and pos-
sibly of genetic factors and the effects of inflammatory 
cytokines. In addition, patients may have inadequate 
intake of calcium in their diets (54). Negative calcium 
balance is one of several factors contributing to bone 
disease in IBD patients, together with glucocorticoid 
treatment and pubertal delay. All patients with IBD 
should be monitored for the right intake of calcium 
(1300 mg daily in adolescents and 1000 to 1500 mg 
daily in adults) and vitamin D (600 International 
Units daily).
Phosphate deficiency may occur in patients with 
chronic diarrhea because of malabsorption of phos-
phate and vitamin D, but rarely with the only poor 
intake. In malnourished patients, sudden increases in 
nutrition (refeeding syndrome) can cause acute hy-
pophosphatemia. As a consequence, malnourished 
patients with CD and chronic diarrhea are at risk for 
hypophosphatemia and require close monitoring and 
phosphate replacement.
Selenium is a co-factor of glutathione periodox-
ase (75). Deficient levels of selenium are more com-
mon among patients with CD who have undergone 
small bowel resection of >200 cm and those receiving 
exclusive enteral nutrition (76-78).
Copper, normally required for iron absorption, is 
an essential trace element used in many enzyme com-
plexes, and its deficiency abnormally-formed hair, de-
pigmentation of the skin, and microcytic anemia. The 
neurologic manifestations include ataxia, neuropathy, 
and cognitive deficits that can mimic vitamin B12 de-
ficiency. Most adults and children with IBD do not 
demonstrate copper deficiency; conversely, some se-
ries report relatively high copper levels (70,78-80,81). 
However, increased losses are observed in those with 
profuse diarrhea, fistulas, or ostomies, or those main-
tained on parenteral nutrition without mineral supple-
ments (82,83).
Magnesium deficiency, which may contribute to 
osteopenia in patients with IBD, may result from de-
creased oral intake, malabsorption, increased intesti-
nal losses, or low concentrations of magnesium in a 
formula used for enteral nutrition (84-86). Mild or 
chronic deficiencies can be supplemented orally with 
magnesium chloride.
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In conclusion, to assess exhaustively the nutritional 
status of IBD patients, hemoglobin, albumin, vitamin 
D, and vitamin B12 in patients with Crohn’s disease af-
fecting the terminal ileum should be monitored. Meas-
urement of serum concentrations of folate, vitamins A 
and E, parathyroid hormone, prothrombin time, mag-
nesium, calcium, phosphorus and zinc may also be indi-
cated based upon disease severity and location.
Dietary interventions in inflammatory bowel disease
Elimination Diet
The use of an exclusion diet trial should elimi-
nate the possibility of an adverse food reaction. In fact, 
many patients can identify foods that they believe may 
precipitate or worsen their disease and it is reasonable 
for them to avoid such foods. Using an elimination 
diet to identify at-risk foods may decrease the possi-
bility of a “flare” of IBD. 
In a multicentre trial (87), 78 patients who had 
achieved remission with elemental diet were randomly 
assigned to corticosteroids (n = 38) or diet (n = 40). 
Median remission time was 3.8 months in the corti-
costeroid group vs 7.5 months in the diet group, and 
relapse rates at 2 years were 79% in the corticosteroid 
group vs 62% in the diet group, significantly favouring 
the diet for maintenance of remission. Food intoler-
ance was mainly to cereals, dairy products and yeast 
(87).
In the study performed by Jones and coworkers, 
the authors evaluated the use of an elimination diet 
versus an unrefined carbohydrate, fiber-rich diet in pa-
tients with CD who were currently in remission. Re-
lapse rates at six months were 100 percent in the unre-
fined carbohydrate, fiber-rich diet versus 30 percent on 
the elimination diet (88).
In the study performed by Giaffer and coworkers, 
Twenty-seven patients with established Crohn’s dis-
ease who attained clinical remission after four weeks 
of enteral feeding were followed prospectively for 
up to 36 months. Twenty of these were willing to be 
tested for specific food intolerance using a pre-defined 
dietary elimination protocol; the others continued on a 
normal unrestricted diet. Eighteen patients (67%) have 
since relapsed; 89% of the relapse occurred within the 
first 6 months. Of the 14 patients who completed the 
process of dietary testing, 5 could not identify any trig-
ger foods; the remaining 9 were maintained on exclu-
sion diets, 3 of whom relapsed early. Of the 11 taking 
a normal diet, 9 relapsed. Disease duration, previous 
intestinal resection or prior steroid therapy did not af-
fect the relapse rate (89). 
Finally, lactose elimination can be particularly 
beneficial. Lactose intolerance is frequently noted in 
patients with ulcerative colitis. A lactose hydrogen 
breath test, performed in this context, may be help-
ful to confirm the diagnosis. To avoid the risk of bone 
loss, Calcium supplementation should be maintained 
in such patients.
Probiotics
In recent years, we have increased our knowledge 
of the immunoregulatory function of intestinal micro-
flora and its possible participation in the physiopa-
thology of IBD (90,91). Alteration of the composition 
and function of intestinal microbiota could lead to in-
creased stimulation of the intestinal immune system, 
epithelial dysfunction and greater permeability of the 
mucosa, and accordingly, the correct characterization 
of the components of these microflora and the defini-
tion of their functions are vital in order to consider 
probiotic treatment for IBD (92,93). Probiotics have 
shown to be as effective as mesalazine in preventing re-
lapses in patients with UC (94) and in the treatment of 
pouchitis (95). On the other hand, there have not been 
convincing data on the efficacy of various probiotics 
for the prevention of relapse in CD (96).
Dietary fiber and prebiotics
In a retrospective study (97), 32 patients with CD, 
treated with a fibre-rich, unrefined-carbohydrate diet 
had a reduced rate of hospital admission and surgeries 
as compared with 32 patients in the non-diet-treated 
group. The outcome suggested that treatment with a 
fibre-rich, unrefined-carbohydrate diet has a favour-
able effect on the clinical course of CD. Germinated 
barley foodstuff (GBF) is a prebiotic that effectively 
increases luminal butyrate production by stimulating 
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the growth of protective bacteria. Several open-label 
trials have reported that oral GBF reduced clinical 
activity (98,99), and prolonged remission time in pa-
tients with UC (100). However, further large clinical 
trials are necessary to validate the efficacy of dietary 
fibre as prebiotics in the management of IBD.
Omega-3 polyunsaturated fatty acids (PUFAs)
The beneficial effect of n-3 PUFAs in Crohn’s dis-
ease patients with high C-reactive protein and eryth-
rocyte sedimentation rate is supported by of a supple-
ment containing fish oil and antioxidants In a rand-
omized placebo-controlled trial evaluating the benefi-
cial effect of n-3 PUFAs in 31 CD patients receiving 
fish oil (101), greater proportions of docosahexaenoic 
acid and eicosapentanoic acid were incorporated into 
peripheral mononuclear cells as compared with arachi-
donic acid, and these patients exhibited lower produc-
tion of both interferon-gamma, and prostaglandin-E2. 
Another study, evaluating the role of oral vitamins 
(102), found that supplementation with vitamins 
C and E decreased oxidative stress, as estimated by 
breath pentane and plasma lipid peroxides, in 51 CD 
patients as compared with normal individuals. How-
ever, neither of these studies found that treatment re-
duced disease activity. Two large placebo-controlled 
trials in CD (103) and systematic reviews of clinical 
trials in patients with UC and CD (104,105) found 
that oral ingested fish oil supplementation, while safe, 
is ineffective for inducing or maintaining remission in 
either UC or CD. 
Enteral nutrition
In a systematic review performed by Zachos 
and coworkers (106), corticosteroids were proved 
to be more effective than enteral nutrition in induc-
ing remission in active CD. Although corticosteroids 
are clearly superior to enteral nutrition, it should be 
highlighted that the response rate to enteral nutrition 
is much greater than one would expect with placebo, 
probably indicating that enteral nutrition does have a 
role to play in the treatment of CD. 
It is important consider that enteral nutrition pre-
sents with fewer side effects than corticosteroids. The 
therapeutic mechanisms of enteral nutrition in CD re-
main unknown. 
Initially it was suggested that the antigenicity 
of dietary protein would trigger bowel inflammation. 
However, the previously mentioned meta-analysis 
(106) failed to identify differences in remission rates 
with amino acid, peptide, or whole protein based diets. 
Fat composition has seldom been taken into account 
when comparing the effect of diet in CD. 
The first randomized, controlled trial in which el-
emental diets containing different fat percentages were 
used to treat patients with active Crohn’s disease (107) 
was performed in 2003 by Bamba and coworkers. In 
this study, patients received one of three doses of fat in 
an elemental dietary supplement for 4 weeks: 10 pa-
tients received a low fat diet (3.06 g/day), 10 patients 
received a medium fat diet (16.56 g/day), and eight pa-
tients received a high fat diet (30.06 g/day). The addi-
tional fat was composed of long chain fatty acids. It was 
showed that C-reactive protein and erythrocyte sedi-
mentation rate decreased in the low fat group, whereas 
the values of these parameters in the medium and high 
fat groups fluctuated during the study. The remission 
rates after 4 weeks were 80%, 40%, and 25% for pa-
tients in the low fat, medium fat, and high fat groups, 
respectively. In another study (108), two enteral diets 
with identical macronutrient distribution but different 
qualitative fat composition were compared. The oral 
diet consisted of oleic acid, linoleic acid, or prednisone, 
and was administered to patients with active CD for 
4 weeks. Twenty per cent of patients taking the oleic 
acid went into remission, whereas 52% of patients tak-
ing the linoleic acid went into remission; the remission 
rate for the steroid group was 79%. These data show 
how the type of dietary fat may be of importance to the 
therapeutic effect of enteral nutrition in CD.
immunomodulatory properties. With regard to 
the pediatric setting, an open trial evaluated an en-
teral formula produced with whole milk that is rich in 
transforming growth factor-b2 in 29 pediatric patients 
(109). Clinical remission occurred after consuming 
this product for 8 weeks as the sole source of nutrition 
in 79% of the study participants. Patients with ileal 
disease were noted to have the greatest improvement.
In a retrospective study of 45 adults with CD, the 
aforementioned enteral formula induced remission in 
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nearly half of the patients studied (110). A majority of 
these patients were resistant or intolerant to immuno-
suppressants. The efficacy of the product was noted to 
be greater in patients with acute inflammation, char-
acterized by elevated C-reactive protein at treatment 
initiation. 
Application of specific nutrients has also been 
studied using the parenteral route of administration. 
Studies in animal models of IBD suggested that glu-
tamine enriched enteral nutrition decreases bacterial 
translocation and stimulates mucosal secretion of im-
munoglobulin A (111).
Finally, although most trials using enteral nutri-
tion have been performed in patients with active dis-
ease, a study (112) has evaluated the role of enteral 
nutrition in the prevention of clinical relapse after sur-
gery for CD. In this report the consumption of at least 
1200 kcal/day of enteral nutrition was associated with 
a lower rate of disease relapse, especially in patients 
who underwent surgery for penetrating disease. Per-
haps this mode of treatment should be considered in a 
selected group of patients with aggressive disease.
Finally, limited data exist on enteral nutritional 
therapy in patients with UC. One prospective  rand-
omized trial compared enteral nutrition with total par-
enteral nutrition as an adjunct therapy in severe UC 
patients on glucocorticoid therapy (113). Remission 
rates were similar in the two groups.
Total parenteral nutrition
Parenteral nutrition can provide nutrition to pa-
tients with active disease and intolerance to enteral 
feedings, presence of obstruction and/or stricture, 
presence of  a distal fistula with inability to feed be-
yond site, or with severe short bowel syndrome (ap-
proximately less than 150 cm of small bowel remain-
ing).
Use of PN has not been found to be effective as 
primary therapy in CD or UC (113). The use of perio-
perative PN has not been carefully studied in IBD and 
may be used for severely malnourished patients who 
meet the above criteria. The American Gastroentero-
logical Association technical review of six trials con-
cluded that TPN provided no benefit in the routine 
treatment of IBD and may be equivalent to enteral 
nutrition when treating patients with active CD of the 
small bowel (114).
Conclusions
Nutrition plays an important role in the patho-
genesis and treatment of CD and UC. Ongoing nu-
trition assessment and a multidisciplinary approach 
are useful tools to manage IBD patients. Nutritional 
supplementation is essential for patients with evidence 
of malnutrition to increase calorie and protein intake. 
Nutritional supplementation can also have efficacy in 
the induction and maintenance of remission in adults 
with CD, however it does not replace other treatments.
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